Relationship between the changes of angiotensin II and vascular endothelial growth factor in plasma and the occurrence of diabetic nephropathy
Xinru Guo
Abstract
Xinru Guo
Abstract
AIM: To measure the concentrations of angiotensinⅡ(ATⅡ) and vascular endothelial growth factor(VEGF) in plasma of diabetics and investigate the relationship between ATⅡ and VEGF and the role of VEGF in occurrence and development of diabetic nephropathy(DN). METHODS: 98 type Ⅱ diabetics were divided into two groups: 43 were in diabetic nephropathy group and 55 in non-diabetic nephropathy (NDN) group, and 25 healty persons were in control group. We measured the levels of ATⅡ, VEGF, glycosylated hemoglobinC (GHbAlc) in plasma and urinary microalbumin(UmALB), respectively. RESULTS: The levels of ATⅡ, VEGF, HbAlc and UmALB in DN group and NDN group were increased significantly compared with control group( P 0 01); The concentrations of ATⅡ, VEGF and UmALB in DN group were obviously higher than that in NDN group( P 0 01), but there was no significant difference of GHbAlc between DN and NDN; There was a positive correlation between ATⅡ and VEGF( r= 0 465, P 0 05), and VEGF was positively correlated with UmALB( r= 0 540, P 0 01). CONCLUSION: The levels of ATⅡand VEGF increased significantly in plasma of diabetics, and ATⅡ and VEGF may involve in the occurrence and development of diabetic nephropathy.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
AIM: To measure the concentrations of angiotensinⅡ(ATⅡ) and vascular endothelial growth factor(VEGF) in plasma of diabetics and investigate the relationship between ATⅡ and VEGF and the role of VEGF in occurrence and development of diabetic nephropathy(DN). METHODS: 98 type Ⅱ diabetics were divided into two groups: 43 were in diabetic nephropathy group and 55 in non-diabetic nephropathy (NDN) group, and 25 healty persons were in control group. We measured the levels of ATⅡ, VEGF, glycosylated hemoglobinC (GHbAlc) in plasma and urinary microalbumin(UmALB), respectively. RESULTS: The levels of ATⅡ, VEGF, HbAlc and UmALB in DN group and NDN group were increased significantly compared with control group( P 0 01); The concentrations of ATⅡ, VEGF and UmALB in DN group were obviously higher than that in NDN group( P 0 01), but there was no significant difference of GHbAlc between DN and NDN; There was a positive correlation between ATⅡ and VEGF( r= 0 465, P 0 05), and VEGF was positively correlated with UmALB( r= 0 540, P 0 01). CONCLUSION: The levels of ATⅡand VEGF increased significantly in plasma of diabetics, and ATⅡ and VEGF may involve in the occurrence and development of diabetic nephropathy.
Key concepts: Diabetic nephropathy, Vascular endothelial growth factor, Internal medicine, Endocrinology, VEGF receptors, Medicine, Diabetes mellitus, Nephropathy